PSYCH OpenIR  > 健康与遗传心理学研究室
Predicting beneficial effects of atomoxetine and citalopram on response inhibition in Parkinson's disease with clinical and neuroimaging measures
Ye, Zheng1,2; Rae, Charlotte L.1,3; Nombela, Cristina1; Ham, Timothy1; Rittman, Timothy1; Jones, Peter Simon1; Rodriguez, Patricia Vazquez1; Coyle-Gilchrist, Ian1; Regenthal, Ralf4; Altena, Ellemarije1; Housden, Charlotte R.1; Maxwell, Helen1; Sahakian, Barbara J.6,7; Barker, Roger A.1; Robbins, Trevor W.5,7; Rowe, James B.1,3,7
2016-03-01
发表期刊HUMAN BRAIN MAPPING
ISSN1065-9471
文章类型Article
卷号37期号:3页码:1026-1037
摘要Recent studies indicate that selective noradrenergic (atomoxetine) and serotonergic (citalopram) reuptake inhibitors may improve response inhibition in selected patients with Parkinson's disease, restoring behavioral performance and brain activity. We reassessed the behavioral efficacy of these drugs in a larger cohort and developed predictive models to identify patient responders. We used a double-blind randomized three-way crossover design to investigate stopping efficiency in 34 patients with idiopathic Parkinson's disease after 40mg atomoxetine, 30mg citalopram, or placebo. Diffusion-weighted and functional imaging measured microstructural properties and regional brain activations, respectively. We confirmed that Parkinson's disease impairs response inhibition. Overall, drug effects on response inhibition varied substantially across patients at both behavioral and brain activity levels. We therefore built binary classifiers with leave-one-out cross-validation (LOOCV) to predict patients' responses in terms of improved stopping efficiency. We identified two optimal models: (1) a clinical model that predicted the response of an individual patient with 77-79% accuracy for atomoxetine and citalopram, using clinically available information including age, cognitive status, and levodopa equivalent dose, and a simple diffusion-weighted imaging scan; and (2) a mechanistic model that explained the behavioral response with 85% accuracy for each drug, using drug-induced changes of brain activations in the striatum and presupplementary motor area from functional imaging. These data support growing evidence for the role of noradrenaline and serotonin in inhibitory control. Although noradrenergic and serotonergic drugs have highly variable effects in patients with Parkinson's disease, the individual patient's response to each drug can be predicted using a pattern of clinical and neuroimaging features. Hum Brain Mapp 37:1026-1037, 2016. (c) 2016 Wiley Periodicals, Inc.
关键词Parkinson's disease impulsivity response inhibition stratification noradrenaline serotonin machine learning
DOI10.1002/hbm.23087
收录类别SCI
语种英语
项目资助者Wellcome Trust(103838) ; Medical Research Council(MC_US_A060_0016 ; NIHR Cambridge Biomedical Research Centre ; Parkinson's UK ; RG62761)
WOS研究方向Neurosciences & Neurology ; Radiology, Nuclear Medicine & Medical Imaging
WOS类目Neurosciences ; Neuroimaging ; Radiology, Nuclear Medicine & Medical Imaging
WOS记录号WOS:000370243600014
WOS标题词Science & Technology ; Life Sciences & Biomedicine
关键词[WOS]IMPULSE CONTROL DISORDERS ; STOP-SIGNAL ; NEUROCHEMICAL MODULATION ; EXTRACELLULAR LEVELS ; PREFRONTAL CORTEX ; WORKING-MEMORY ; DOPAMINE ; SEROTONIN ; BRAIN ; METHYLPHENIDATE
引用统计
文献类型期刊论文
条目标识符http://ir.psych.ac.cn/handle/311026/19568
专题健康与遗传心理学研究室
作者单位1.Univ Cambridge, Dept Clin Neurosci, Herchel Smith Bldg,Forvie Site,Robinson Way,Cambr, Cambridge CB2 0SZ, England
2.Chinese Acad Sci, Inst Psychol, Key Lab Mental Hlth, Beijing 100101, Peoples R China
3.MRC, Cognit & Brain Sci Unit, Cambridge, England
4.Univ Leipzig, Rudolf Boehm Inst Pharmacol & Toxicol, Div Clin Pharmacol, D-04109 Leipzig, Germany
5.Univ Cambridge, Dept Psychol, Cambridge CB2 0SZ, England
6.Univ Cambridge, Dept Psychiat, Cambridge CB2 0SZ, England
7.Behav & Clin Neurosci Inst, Cambridge, England
推荐引用方式
GB/T 7714
Ye, Zheng,Rae, Charlotte L.,Nombela, Cristina,et al. Predicting beneficial effects of atomoxetine and citalopram on response inhibition in Parkinson's disease with clinical and neuroimaging measures[J]. HUMAN BRAIN MAPPING,2016,37(3):1026-1037.
APA Ye, Zheng.,Rae, Charlotte L..,Nombela, Cristina.,Ham, Timothy.,Rittman, Timothy.,...&Rowe, James B..(2016).Predicting beneficial effects of atomoxetine and citalopram on response inhibition in Parkinson's disease with clinical and neuroimaging measures.HUMAN BRAIN MAPPING,37(3),1026-1037.
MLA Ye, Zheng,et al."Predicting beneficial effects of atomoxetine and citalopram on response inhibition in Parkinson's disease with clinical and neuroimaging measures".HUMAN BRAIN MAPPING 37.3(2016):1026-1037.
条目包含的文件
文件名称/大小 文献类型 版本类型 开放类型 使用许可
Predicting beneficia(390KB)期刊论文作者接受稿限制开放CC BY-NC-SA浏览 请求全文
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Ye, Zheng]的文章
[Rae, Charlotte L.]的文章
[Nombela, Cristina]的文章
百度学术
百度学术中相似的文章
[Ye, Zheng]的文章
[Rae, Charlotte L.]的文章
[Nombela, Cristina]的文章
必应学术
必应学术中相似的文章
[Ye, Zheng]的文章
[Rae, Charlotte L.]的文章
[Nombela, Cristina]的文章
相关权益政策
暂无数据
收藏/分享
文件名: Predicting beneficial effects of atomoxetine and citalopram on response inhibition in Parkinson's disease with clinical and neuroimaging measures.pdf
格式: Adobe PDF
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。